Literature DB >> 15853671

From discovery to clinical trials: treatment strategies for central neuropathic pain after spinal cord injury.

Claire E Hulsebosch1.   

Abstract

Spinal cord injuries (SCI) result in a devastating loss of function below the level of the lesion in which there are variable motor recoveries and, in the majority of cases, central neuropathic pain syndromes (CNP) develop several months to years following injury. Unfortunately, the study of chronic pain after SCI has been neglected in the past due in part to the lack of good animal models but largely due to the clinically held dogma that CNP is not a real phenomenon and is psychogenic in nature rather than based on described pathophysiological mechanisms. The purpose of this article is to offer standardized terminology of pain, insight into animal modeling issues of CNP, descriptions of current clinical therapies and to discuss the pathophysiological mechanisms that provide the substrate for CNP that will lead to innovative new therapies. It is hoped that this information will give insight for research strategies as well as better care not only of SCI individuals, but is generalizable to many other CNP syndromes.

Entities:  

Mesh:

Year:  2005        PMID: 15853671     DOI: 10.2174/1381612053507864

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  18 in total

1.  Inflammatory consequences in a rodent model of mild traumatic brain injury.

Authors:  J Regino Perez-Polo; Harriet C Rea; Kathia M Johnson; Margaret A Parsley; Geda C Unabia; Guojing Xu; Smitha K Infante; Douglas S Dewitt; Claire E Hulsebosch
Journal:  J Neurotrauma       Date:  2013-05-06       Impact factor: 5.269

2.  Expression profile of flotillin-2 and its pathophysiological role after spinal cord injury.

Authors:  José M Santiago; Aranza I Torrado; Luz C Arocho; Odrick R Rosas; Ana E Rodríguez; Franchesca König Toro; Iris K Salgado; Yaría Arroyo Torres; Walter I Silva; Jorge D Miranda
Journal:  J Mol Neurosci       Date:  2012-08-10       Impact factor: 3.444

3.  Central Neuropathic Pain in Spinal Cord Injury.

Authors:  Sujin Lee; Xing Zhao; Maya Hatch; Sophia Chun; Eric Chang
Journal:  Crit Rev Phys Rehabil Med       Date:  2013

4.  Acute and chronic tactile sensory testing after spinal cord injury in rats.

Authors:  Megan Ryan Detloff; Lesley C Fisher; Rochelle J Deibert; D Michele Basso
Journal:  J Vis Exp       Date:  2012-04-04       Impact factor: 1.355

5.  Transplanted astrocytes derived from BMP- or CNTF-treated glial-restricted precursors have opposite effects on recovery and allodynia after spinal cord injury.

Authors:  Jeannette E Davies; Christoph Pröschel; Ningzhe Zhang; Mark Noble; Margot Mayer-Pröschel; Stephen J A Davies
Journal:  J Biol       Date:  2008-09-19

6.  Gliopathy ensures persistent inflammation and chronic pain after spinal cord injury.

Authors:  Claire E Hulsebosch
Journal:  Exp Neurol       Date:  2008-07-29       Impact factor: 5.330

7.  Activation of p38 MAP kinase is involved in central neuropathic pain following spinal cord injury.

Authors:  Eric D Crown; Young Seob Gwak; Zaiming Ye; Kathia M Johnson; Claire E Hulsebosch
Journal:  Exp Neurol       Date:  2008-06-12       Impact factor: 5.330

8.  Molecular, anatomical, physiological, and behavioral studies of rats treated with buprenorphine after spinal cord injury.

Authors:  José M Santiago; Odrick Rosas; Aranza I Torrado; María M González; Priya O Kalyan-Masih; Jorge D Miranda
Journal:  J Neurotrauma       Date:  2009-10       Impact factor: 5.269

9.  Spinal cord injury-induced attenuation of GABAergic inhibition in spinal dorsal horn circuits is associated with down-regulation of the chloride transporter KCC2 in rat.

Authors:  Yan Lu; Jihong Zheng; Lize Xiong; Manfred Zimmermann; Jing Yang
Journal:  J Physiol       Date:  2008-10-09       Impact factor: 5.182

10.  Attenuation of spinal cord injury-induced astroglial and microglial activation by repetitive transcranial magnetic stimulation in rats.

Authors:  Ji Young Kim; Gyu-Sik Choi; Yun-Woo Cho; Heekyung Cho; Se-Jin Hwang; Sang-Ho Ahn
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.